Earnings History
EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.26%
Period
EPS Actual
EPS Est
Surprise
March 31, 2026
$-1.46
$-1.22
-0.24%
Dec. 31, 2025
$-1.03
$-1.20
0.17%
Sept. 30, 2025
$-1.12
$-1.75
0.63%
June 30, 2025
$-1.76
$-2.00
0.24%
March 31, 2025
$-1.68
$-2.12
0.44%
Dec. 31, 2024
$-2.00
$-2.34
0.34%
Peer comparison (GICS sub-industry)
Key metrics vs sector peers
Ticker
Market Cap
P/E
Rev YoY
Net Margin
ROE
Gross Margin
RLYB
$4M
-0.4
34.9%
-1046.4%
-17.3%
—
ALDX
$312M
-9.2
—
—
-68.0%
—
FBIO
—
—
—
—
—
—
GANX
$135M
-5.3
-60.6%
—
-181.1%
—
ICCC
—
-51.2
4.3%
—
—
—
KLRS
$193M
-3.0
—
—
-65.8%
—
ACRV
$76M
-1.2
—
—
-61.0%
—
ATRA
$132M
7.0
-6.3%
27.1%
-88.9%
—
ACET
—
-0.5
—
—
—
—
Full Fundamentals
All metrics by year — income statement, balance sheet, cash flow
Income Statement14
Annual Income Statement data for RLYB
Metric
Trend
2025
2024
Revenue
$858.0K
$636.0K
R&D Expense
$20M
$42M
SG&A Expense
$14M
$20M
Operating Expenses
$34M
$61M
Operating Income
$-33M
$-60M
Other Non-op
$23M
$744.0K
Pretax Income
$-9M
$-56M
Income Tax
$0
$0
Net Income
$-9M
$-58M
EPS (Basic)
$-1.59
$-10.61
EPS (Diluted)
$-1.59
$-10.61
Shares (Basic)
5,629,370
5,443,332
Shares (Diluted)
5,629,370
5,443,332
EBITDA
$-33M
$-60M
Balance Sheet22
Annual Balance Sheet data for RLYB
Metric
Trend
2025
2024
Cash & Equivalents
$31M
$14M
Short-term Investments
$23M
$52M
Prepaid Expense
$7M
$2M
Other Current Assets
$3M
$995.0K
Current Assets
$61M
$68M
PP&E (Net)
$23.0K
$115.0K
PP&E (Gross)
$503.0K
$769.0K
Accum. Depreciation
$480.0K
$654.0K
Other Non-current Assets
$810.0K
$0
Total Assets
$62M
$68M
Accounts Payable
$126.0K
$278.0K
Accrued Liabilities
$4M
$5M
Current Liabilities
$4M
$6M
Capital Leases
$82.0K
$0
Total Liabilities
$4M
$6M
Common Stock
$4.0K
$4.0K
Paid-in Capital
$360M
$355M
Retained Earnings
$-302M
$-293M
AOCI
$18.0K
$68.0K
Stockholders' Equity
$58M
$62M
Liabilities + Equity
$62M
$68M
Shares Outstanding
5,283,321
5,188,743
Cash Flow10
Annual Cash Flow data for RLYB
Metric
Trend
2025
2024
D&A
$92.0K
$131.0K
Stock-based Comp
$5M
$8M
Operating Cash Flow
$-30M
$-49M
CapEx
·
$0
Investing Cash Flow
$47M
$33M
Stock Issued
$0
$5M
Net Stock Activity
$0
$5M
Financing Cash Flow
$16.0K
$5M
Net Change in Cash
$17M
$-11M
Free Cash Flow
·
$-49M
Profitability7
Annual Profitability data for RLYB
Metric
Trend
2025
2024
Operating Margin
-3853.6%
-10082.7%
Net Margin
-1046.4%
-9629.2%
Pretax Margin
-1046.4%
-9256.0%
EBITDA Margin
-3853.6%
-10082.7%
ROA
-13.8%
-62.9%
ROE
-17.3%
-87.2%
ROIC
-57.0%
-98.1%
Liquidity & Solvency2
Annual Liquidity & Solvency data for RLYB
Metric
Trend
2025
2024
Current Ratio
14.5
10.9
Quick Ratio
13.0
10.5
Efficiency1
Annual Efficiency data for RLYB
Metric
Trend
2025
2024
Asset Turnover
0.0
0.0
Per Share5
Annual Per Share data for RLYB
Metric
Trend
2025
2024
Book Value / Share
$10.97
$1.49
Revenue / Share
$0.15
$0.01
Cash Flow / Share
$-5.30
$-1.13
Cash / Share
$5.94
$0.33
EPS (TTM)
$-1.59
$-10.61
Growth Rates1
Annual Growth Rates data for RLYB
Metric
Trend
2025
2024
Revenue YoY
34.9%
·
Valuation (TTM)10
Annual Valuation (TTM) data for RLYB
Metric
Trend
2025
2024
Revenue TTM
$858.0K
$636.0K
Net Income TTM
$-9M
$-58M
Market Cap
$4M
$40M
P/E
-0.4
-0.1
P/S
4.2
62.7
P/B
0.1
0.6
P / Tangible Book
0.1
0.6
P / Cash Flow
-0.1
-0.8
P / FCF
·
-0.8
Earnings Yield
-231.8%
-1105.2%
Income Statement14
Quarterly Income Statement data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Revenue
$0
$212.0K
$222.0K
$212.0K
$212.0K
$212.0K
$38.0K
$299.0K
$299.0K
$0
·
$0
$0
R&D Expense
$758.0K
$3M
$4M
$4M
$6M
$6M
$7M
$8M
$13M
$13M
$16M
$13M
$13M
SG&A Expense
$5M
$6M
$3M
$3M
$4M
$4M
$4M
$4M
$4M
$7M
$5M
$6M
$7M
Operating Expenses
$6M
$9M
$7M
$7M
$10M
$10M
$12M
$12M
$17M
$20M
$21M
$19M
$20M
Operating Income
$-6M
$-9M
$-6M
$-7M
$-10M
$-10M
$-12M
$-12M
$-17M
$-20M
$-21M
$-19M
$-20M
Other Non-op
$424.0K
$254.0K
$0
$22M
$118.0K
$174.0K
$183.0K
$251.0K
$143.0K
$167.0K
$35.0K
$92.0K
$62.0K
Pretax Income
$45M
$-8M
$-7M
$16M
$-9M
$-9M
·
$-11M
$-16M
$-18M
$-20M
$-18M
$-18M
Income Tax
$1M
·
·
·
$0
·
·
·
·
·
·
·
·
Net Income
$44M
$-8M
$-6M
$16M
$-10M
$-9M
$-11M
$-11M
$-16M
$-19M
$-20M
$-18M
$-19M
EPS (Basic)
$7.66
$-1.46
$-1.52
$0.36
$-1.73
$-1.69
$-9.51
$-0.26
$-0.37
$-0.47
$-0.50
$-0.45
$-0.46
EPS (Diluted)
$7.53
$-1.46
$-1.52
$0.36
·
$-1.69
$-9.51
$-0.26
$-0.37
$-0.47
$-0.50
$-0.45
$-0.46
Shares (Basic)
5,699,111
5,688,584
-129,044,963
45,058,591
5,605,116
5,597,528
-124,051,563
44,593,221
44,128,059
40,773,615
-80,696,904
40,531,497
40,363,902
Shares (Diluted)
5,797,913
5,688,584
-129,044,963
45,058,591
·
5,597,528
-124,051,563
44,593,221
44,128,059
40,773,615
-80,696,904
40,531,497
40,363,902
EBITDA
$-6M
$-9M
·
$-7M
$-10M
$-10M
·
$-12M
$-17M
$-20M
·
$-19M
$-20M
Balance Sheet22
Quarterly Balance Sheet data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Cash & Equivalents
$93M
$41M
$31M
$32M
$9M
$15M
$14M
$25M
$17M
$19M
$24M
$19M
$33M
Short-term Investments
$0
$5M
$23M
$27M
$36M
$40M
$52M
$50M
$72M
$75M
$85M
$102M
$105M
Prepaid Expense
$4M
$7M
$7M
$7M
$5M
$3M
$2M
$3M
$3M
$4M
$5M
$11M
$9M
Other Current Assets
$4M
$6M
$3M
$3M
$573.0K
$872.0K
$995.0K
$2M
$1M
$768.0K
$2M
$4M
$1M
Current Assets
$97M
$53M
$61M
$67M
$50M
$57M
$68M
$78M
$91M
$99M
$115M
$132M
$147M
PP&E (Net)
$0
$20.0K
$23.0K
$26.0K
$61.0K
$87.0K
$115.0K
$145.0K
$177.0K
$211.0K
$246.0K
$282.0K
$308.0K
PP&E (Gross)
·
·
$503.0K
·
·
·
$769.0K
·
·
·
$769.0K
·
·
Accum. Depreciation
·
·
$480.0K
·
·
·
$654.0K
·
·
·
$523.0K
·
·
Other Non-current Assets
$810.0K
$810.0K
$810.0K
$810.0K
·
·
$0
·
·
·
·
·
·
Total Assets
$98M
$54M
$62M
$68M
$51M
$58M
$68M
$79M
$92M
$99M
$116M
$133M
$148M
Accounts Payable
$833.0K
$940.0K
$126.0K
$269.0K
$119.0K
$400.0K
$278.0K
$583.0K
$1M
$470.0K
$976.0K
$464.0K
$689.0K
Accrued Liabilities
$1M
$3M
$4M
$4M
$4M
$3M
$5M
$6M
$10M
$9M
$8M
$9M
$7M
Current Liabilities
$4M
$4M
$4M
$5M
$5M
$4M
$6M
$8M
$12M
$10M
$9M
$9M
$8M
Capital Leases
$0
$55.0K
$82.0K
$108.0K
·
·
$0
$0
$58.0K
$116.0K
$173.0K
$211.0K
$266.0K
Total Liabilities
$4M
$4M
$4M
$5M
$5M
$4M
$6M
$8M
$12M
$10M
$9M
$10M
$8M
Common Stock
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
$4.0K
Paid-in Capital
$361M
$361M
$360M
$359M
$358M
$356M
$355M
$353M
$351M
$343M
$341M
$339M
$336M
Retained Earnings
$-267M
$-310M
$-302M
$-296M
$-312M
$-302M
$-293M
$-282M
$-271M
$-254M
$-235M
$-215M
$-197M
AOCI
$0
$1.0K
$18.0K
$24.0K
$17.0K
$47.0K
$68.0K
$169.0K
$-71.0K
$-71.0K
$15.0K
$-208.0K
$-272.0K
Stockholders' Equity
$94M
$50M
$58M
$63M
$46M
$54M
$62M
$71M
$80M
$89M
$106M
$124M
$139M
Liabilities + Equity
$98M
$54M
$62M
$68M
$51M
$58M
$68M
$79M
$92M
$99M
$116M
$133M
$148M
Shares Outstanding
5,306,894
5,290,236
5,283,321
41,935,841
41,707,153
41,612,039
5,188,743
41,487,586
41,487,586
37,811,970
37,829,565
37,800,856
37,790,856
Cash Flow9
Quarterly Cash Flow data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
D&A
$2.0K
$3.0K
$3.0K
$35.0K
$26.0K
$28.0K
$30.0K
$32.0K
$34.0K
$35.0K
$36.0K
$37.0K
$38.0K
Stock-based Comp
$424.0K
$613.0K
$774.0K
$1M
$2M
$2M
$2M
$2M
$2M
$2M
$3M
$3M
$3M
Operating Cash Flow
$46M
$-8M
$-5M
$-7M
$-8M
$-10M
$-10M
$-14M
$-10M
$-15M
$-12M
$-16M
$-13M
CapEx
·
·
·
·
·
·
·
·
·
·
$12.0K
$0
$0
Investing Cash Flow
$6M
$18M
$4M
$29M
$3M
$11M
$-2M
$22M
$3M
$10M
$17M
$3M
$6M
Stock Issued
·
$3.0K
$0
$0
$0
$0
$0
$0
·
·
$0
$-209.0K
·
Net Stock Activity
·
$3.0K
·
·
·
·
·
·
·
·
·
·
·
Financing Cash Flow
$131.0K
$3.0K
$6.0K
$0
$10.0K
$0
$18.0K
$-11.0K
$5M
$0
$72.0K
$0
$210.0K
Net Change in Cash
$52M
$10M
$-748.0K
$23M
$-5M
$876.0K
$-11M
$9M
$-3M
$-5M
$5M
$-13M
$-7M
Profitability7
Quarterly Profitability data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Operating Margin
·
-4119.3%
·
-3266.5%
-4743.9%
-4561.3%
·
-4035.5%
-5697.3%
·
·
·
·
Net Margin
·
-3904.7%
·
7554.7%
-4576.9%
-4452.4%
·
-3834.8%
-5430.1%
·
·
·
·
Pretax Margin
·
-3904.7%
·
7554.7%
-4441.5%
-4175.5%
·
-3621.7%
-5267.2%
·
·
·
·
EBITDA Margin
·
-4119.3%
·
-3266.5%
-4743.9%
-4561.3%
·
-4035.5%
-5697.3%
·
·
·
·
ROA
58.6%
-14.7%
·
21.8%
-13.5%
-12.0%
·
-10.8%
-13.5%
-14.5%
·
-13.3%
-12.3%
ROE
62.2%
-15.9%
·
23.9%
-15.4%
-13.2%
·
-11.8%
-14.8%
-15.6%
·
-14.4%
-13.0%
ROIC
-5.8%
·
·
·
·
·
·
·
·
·
·
·
·
Liquidity & Solvency2
Quarterly Liquidity & Solvency data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Current Ratio
27.3
12.9
·
14.7
10.0
14.7
·
9.6
7.5
9.8
·
14.1
18.2
Quick Ratio
26.0
11.3
·
13.1
9.1
13.9
·
9.2
7.3
9.3
·
12.9
17.1
Efficiency1
Quarterly Efficiency data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Asset Turnover
0.0
0.0
·
0.0
0.0
0.0
·
0.0
0.0
·
·
·
·
Per Share5
Quarterly Per Share data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Book Value / Share
$17.81
$9.50
·
$1.50
$1.10
$1.30
·
$1.71
$1.93
$2.36
·
$3.27
$3.68
Revenue / Share
$0.00
$0.04
·
$0.00
$0.00
$0.00
·
$0.01
$0.01
·
·
·
·
Cash Flow / Share
·
$-1.40
·
·
·
$-0.23
·
·
·
$-0.38
·
·
·
Cash / Share
$17.50
$7.81
·
$0.77
$0.23
$0.36
·
$0.61
$0.40
$0.51
·
$0.51
$0.86
EPS (TTM)
·
$-3.01
·
$-0.33
$-1.06
$-1.31
·
$-1.55
$-1.75
$-1.81
·
$-1.94
$-2.06
Valuation (TTM)9
Quarterly Valuation (TTM) data for RLYB
Metric
Trend
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Revenue TTM
$636.0K
$848.0K
·
$935.0K
$1M
$810.0K
·
$598.0K
$299.0K
·
·
·
·
Net Income TTM
$42M
$-11M
·
$-15M
$-47M
$-56M
·
$-65M
$-72M
$-73M
·
$-73M
$-72M
Market Cap
$85M
$47M
·
$21M
$14M
$27M
·
$49M
$56M
$70M
·
$127M
$214M
P/E
·
-3.0
·
-1.5
-0.3
-0.5
·
-0.8
-0.8
-1.0
·
-1.7
-2.7
P/S
133.5
56.0
·
22.4
13.8
33.6
·
81.2
185.9
·
·
·
·
P/B
0.9
0.9
·
0.3
0.3
0.5
·
0.7
0.7
0.8
·
1.0
1.5
P / Tangible Book
0.9
0.9
·
0.3
0.3
0.5
·
0.7
0.7
0.8
·
1.0
1.5
P / Cash Flow
·
-5.9
·
·
·
-2.7
·
·
·
-4.5
·
·
·
Earnings Yield
·
-33.6%
·
-66.1%
-313.6%
-200.0%
·
-132.5%
-130.6%
-97.8%
·
-57.6%
-36.4%
Financial Statements
Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
2025-12-31
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Revenue
$858.0K
$636.0K
—
—
—
Operating Margin %
-3853.6%
-10082.7%
—
—
—
Net Income
$-9M
$-58M
$-75M
$-67M
$-47M
Diluted EPS
$-1.59
$-10.61
$-1.84
$-2.09
$-1.84
Balance Sheet
2025-12-31
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Current Ratio
14.5
10.9
12.4
16.7
27.6
Quick Ratio
13.0
10.5
11.9
15.7
26.8
Cash Flow
2025-12-31
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Free Cash Flow
—
$-49M
$-60M
$-57M
$-46M
My Metrics
Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F)
42 filers · $69.2M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
New positions
Exited positions
Increased
Decreased
Net shares change
13
9
7
6
—
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners
5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P. Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited
×2 filings
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership
Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.